Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

NCT02170090 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT02170090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02170090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 30, 2014
Completion date
December 31, 2025
Enrollment
789 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, gall bladder carcinoma